Growing concerns and complaints of risks and wrongful death associated with Pradaxa and similar anti-coagulants has some top U.S. heart doctors hesitating in prescribing the drug, according to a recent Reuters article.
Many cardiologists are calling for a more rigorous monitoring system in patients who are prescribed Pradaxa. Pradaxa is a twice daily pill manufactured by Boehringer Ingelheim. It was approved by the U.S. Food and Drug Administration in October 2010 to prevent strokes in patients with atrial fibrillation, an irregular heartbeat condition. It was the first new oral treatment for that use since warfarin was introduced in the 1950s.
Currently, Pradaxa patients are not required to regularly monitor their blood or have frequent follow-ups with their physician. This raises concerns about the risk of stroke, blood clots and serious bleeding if not taken properly, especially in patients with poor kidney function.
About 545 reports of Pradaxa-related deaths were reported to the FDA in 2011, according to estimates from the Institute for Safe Medication Practices last month. This is significantly higher than the 72 deaths associated with warfarin.
Many lawsuits have been filed against Boehringer Ingelheim, alleging injuries from Pradaxa-use.
If you or a loved one has been prescribed Pradaxa and has experienced adverse side effects, including but not limited to stroke, blood clots, internal bleeding or wrongful death, you may have cause to pursue legal recourse.
For more information on the legal rights which may be available to Pradaxa injury victims and their families, complete the Free Case Evaluation form on this page to schedule a no-obligation consultation with one of our Pradaxa lawyers .